Absorption of oral diphosphonate in normal subjects
- PMID: 3085989
- DOI: 10.1111/j.1365-2265.1986.tb03254.x
Absorption of oral diphosphonate in normal subjects
Abstract
Absorption of the diphosphonate etidronate (HEDP) was measured in 20 volunteer subjects at two centres (Glasgow and Madison) using a new method based on simultaneous administration of HEDP and intravenous 99mTc-HEDP (Osteoscan). The mean absorption of HEDP in fasting subjects in Glasgow was 3.5% (range 1-8.9%) and in Madison 1.5% (0.7-2.8%) (P less than 0.035). In four subjects studies were repeated with good agreement between results (mean 3.9 cf. 3.5%). Six subjects had studies repeated when drug was ingested with food and in all cases absorption was effectively reduced to zero. We conclude that absorption of HEDP is significantly higher in normal subjects in Glasgow than in Madison. This may be of importance with regard to the finding of histological osteomalacia and fracture associated with HEDP use in Glasgow.
Similar articles
-
Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) using a deconvolution technique.Toxicol Appl Pharmacol. 1973 Apr;24(4):580-9. doi: 10.1016/0041-008x(73)90219-6. Toxicol Appl Pharmacol. 1973. PMID: 4197358 No abstract available.
-
Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.J Nucl Med. 2003 Jun;44(6):953-60. J Nucl Med. 2003. PMID: 12791825 Clinical Trial.
-
Dose-dependent absorption of disodium etidronate.J Pharm Pharmacol. 1985 Jun;37(6):443-5. doi: 10.1111/j.2042-7158.1985.tb03035.x. J Pharm Pharmacol. 1985. PMID: 2862272
-
A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1114-24. doi: 10.1007/s00259-003-1197-y. Epub 2003 May 22. Eur J Nucl Med Mol Imaging. 2003. PMID: 12761596 Clinical Trial.
-
Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.J Nucl Med. 2003 Feb;44(2):247-51. J Nucl Med. 2003. PMID: 12571217
Cited by
-
Bisphosphonates in bone diseases.Pharm World Sci. 1998 Oct;20(5):206-13. doi: 10.1023/a:1008626026484. Pharm World Sci. 1998. PMID: 9820883 Review.
-
Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.Ann Rheum Dis. 1986 Dec;45(12):1012-8. doi: 10.1136/ard.45.12.1012. Ann Rheum Dis. 1986. PMID: 3813665 Free PMC article.
-
Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover.Eur J Clin Pharmacol. 1995;48(6):489-94. doi: 10.1007/BF00194339. Eur J Clin Pharmacol. 1995. PMID: 8582468 Clinical Trial.
-
Bisphosphonates and bone metastases.Br J Cancer. 1988 Nov;58(5):556-7. doi: 10.1038/bjc.1988.257. Br J Cancer. 1988. PMID: 3064797 Free PMC article. Review. No abstract available.
-
Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.Drugs. 1993 Oct;46(4):594-617. doi: 10.2165/00003495-199346040-00003. Drugs. 1993. PMID: 7506648 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources